Beyond Air Inc Reports Flat Q1 Revenue, Reaffirms 2026 Guidance Amid Strategic Shift

Beyond Air Inc reported flat quarter-over-quarter revenue of $1.8 million for the first quarter of 2027, attributing the stagnation to the extended sales cycles inherent in hospital contracting. Despite the revenue plateau, the company secured a national group purchasing agreement with a third major U.S. group purchasing organisation (GPO), a move management describes as a critical component for accessing a substantial portion of the US hospital market.

The firm also strengthened its balance sheet through a financing agreement for up to $30 million, which provides $10 million in upfront gross proceeds. These funds are earmarked primarily for operations and the manufacturing of second-generation LungFit PH pilot devices, allowing the company to absorb current cash burn as it scales commercial operations.

Management reaffirmed its calendar year 2026 revenue guidance of $8 million, assuming approximately 15 per cent growth over 2025. This target explicitly excludes any revenue contribution from the second-generation LungFit PH system. CEO Robert Goodman expressed high confidence in meeting this annual target, citing recent contract wins and a doubling of the commercial pipeline over the last five to six months.

Looking ahead, Beyond Air projects 2027 revenue between $16 million and $18 million, contingent on the commercial launch of the Gen II system. The company expects potential FDA approval for the second-generation LungFit PH system in the fourth quarter of 2026, following a desk audit of performance qualifications once final pilot builds are completed.

Beyond Air Inc regained compliance with Nasdaq listing requirements and transitioned its fiscal year-end from March 31 to December 31 to align with calendar-year reporting. The company also reported a third consecutive quarter of positive gross profit, with gross margin improving to 13 per cent from 9 per cent in the prior year period.